Tumor Extracellular Matrix Remodeling: New Perspectives as a Circulating Tool in the Diagnosis and Prognosis of Solid Tumors
暂无分享,去创建一个
Gabriella Sozzi | G. Sozzi | E. Tagliabue | T. Triulzi | M. Giussani | Tiziana Triulzi | Elda Tagliabue | Marta Giussani
[1] P. Mack,et al. Serum Osteopontin Levels are Highly Prognostic for Survival in Advanced Non-small Cell Lung Cancer: Results from JMTO LC 0004 , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[2] C. Colpaert,et al. A fibrotic focus is a prognostic factor and a surrogate marker for hypoxia and (lymph)angiogenesis in breast cancer: review of the literature and proposal on the criteria of evaluation , 2007, Histopathology.
[3] S. Pitson,et al. The Role of the Extracellular Matrix and Its Molecular and Cellular Regulators in Cancer Cell Plasticity , 2018, Front. Oncol..
[4] E. Fadel,et al. Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer , 2016, BMC Cancer.
[5] P. Naredi,et al. Type IV collagen is a tumour stroma-derived biomarker for pancreas cancer , 2009, British Journal of Cancer.
[6] Ugo Pastorino,et al. Diagnostic role of circulating extracellular matrix-related proteins in non-small cell lung cancer , 2018, BMC Cancer.
[7] M. Ayers,et al. Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers , 2008, British Journal of Cancer.
[8] A. Bankfalvi,et al. Matrix metalloproteinase‐7 as a marker of metastasis and predictor of poor survival in bladder cancer , 2010, Cancer science.
[9] Nikos K. Karamanos,et al. Matrix modeling and remodeling: A biological interplay regulating tissue homeostasis and diseases. , 2019, Matrix biology : journal of the International Society for Matrix Biology.
[10] M. Koch,et al. Prognostic impact of a compartment-specific angiogenic marker profile in patients with pancreatic cancer , 2014, OncoTarget.
[11] I. Kovalszky,et al. Validation of Circulating MMP-7 Level as an Independent Prognostic Marker of Poor Survival in Urinary Bladder Cancer , 2011, Pathology & Oncology Research.
[12] M. Yen,et al. A case–cohort study for the disease natural history of adenoma–carcinoma and de novo carcinoma and surveillance of colon and rectum after polypectomy: implication for efficacy of colonoscopy , 2003, British Journal of Cancer.
[13] P. Naredi,et al. Improved tumour marker sensitivity in detecting colorectal liver metastases by combined type IV collagen and CEA measurement , 2015, Tumor Biology.
[14] F. Tanaka,et al. Serum level of osteopontin as a prognostic factor in patients who underwent surgical resection for non-small-cell lung cancer. , 2013, Clinical lung cancer.
[15] J. Angulo,et al. El papel de la metaloproteinasa de la matriz MMP-9 y del inhibidor tisular de metaloproteinasa TIMP-2 como marcadores séricos de cáncer vesical , 2013 .
[16] Jane L Meza,et al. MUC4 Mucin Potentiates Pancreatic Tumor Cell Proliferation, Survival, and Invasive Properties and Interferes with Its Interaction to Extracellular Matrix Proteins , 2007, Molecular Cancer Research.
[17] R. Muschel,et al. A core matrisome gene signature predicts cancer outcome , 2018, British Journal of Cancer.
[18] V. Weaver,et al. The extracellular matrix modulates the hallmarks of cancer , 2014, EMBO reports.
[19] H. Reis,et al. Validation of the diagnostic and prognostic relevance of serum MMP-7 levels in renal cell cancer by using a novel automated fluorescent immunoassay method , 2016, International Urology and Nephrology.
[20] E. Salido,et al. Plasma matrix metalloproteinase 9 as an early surrogate biomarker of advanced colorectal neoplasia. , 2016, Gastroenterologia y hepatologia.
[21] In‐San Kim,et al. Fibronectin on circulating extracellular vesicles as a liquid biopsy to detect breast cancer , 2016 .
[22] Witold Rzyman,et al. European position statement on lung cancer screening. , 2017, The Lancet. Oncology.
[23] Chwee Teck Lim,et al. An extracellular matrix-related prognostic and predictive indicator for early-stage non-small cell lung cancer , 2017, Nature Communications.
[24] Terry Hyslop,et al. Clinical Significance of Serum COL6A3 in Pancreatic Ductal Adenocarcinoma , 2013, Journal of Gastrointestinal Surgery.
[25] Giuseppe Merlino,et al. Tumor-extracellular matrix interactions: Identification of tools associated with breast cancer progression. , 2015, Seminars in cancer biology.
[26] T. Zima,et al. Circulating tumor cells and serum levels of MMP-2, MMP-9 and VEGF as markers of the metastatic process in patients with high risk of metastatic progression. , 2017, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.
[27] M. Karsdal,et al. Collagen degradation products measured in serum can separate ovarian and breast cancer patients from healthy controls: A preliminary study. , 2015, Cancer biomarkers : section A of Disease markers.
[28] R. Sanz-Pamplona,et al. Discovery and Validation of New Potential Biomarkers for Early Detection of Colon Cancer , 2014, PloS one.
[29] P. Sinues,et al. Noninvasive strategies for breast cancer early detection. , 2016, Future oncology.
[30] M. Karsdal,et al. High turnover of extracellular matrix reflected by specific protein fragments measured in serum is associated with poor outcomes in two metastatic breast cancer cohorts , 2018, International journal of cancer.
[31] A. Schneeweiss,et al. Plasma hyaluronic acid level as a prognostic and monitoring marker of metastatic breast cancer , 2016, International journal of cancer.
[32] J. Crowley,et al. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Z. Daniil,et al. Clinical Significance of Circulating Osteopontin Levels in Patients With Lung Cancer and Correlation With VEGF and MMP-9 , 2016, Cancer investigation.
[34] B. Mroczko,et al. The diagnostic value of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patients , 2010, International Journal of Colorectal Disease.
[35] S. Ménard,et al. Neoplastic and Stromal Cells Contribute to an Extracellular Matrix Gene Expression Profile Defining a Breast Cancer Subtype Likely to Progress , 2013, PloS one.
[36] K. Harada,et al. Significance of circulating matrix metalloproteinase-9 to tissue inhibitor of metalloproteinases-2 ratio as a predictor of disease progression in patients with metastatic renal cell carcinoma receiving sunitinib. , 2014, Urologic oncology.
[37] J. Liao,et al. TIMP-1 is a novel serum biomarker for the diagnosis of colorectal cancer: A meta-analysis , 2018, PloS one.
[38] Z. Werb,et al. The Role of Stroma in Tumor Development. , 2015, Cancer journal.
[39] C. Haglund,et al. Serum MMP-8 and TIMP-1 predict prognosis in colorectal cancer , 2018, BMC Cancer.
[40] P. Naredi,et al. Type IV collagen as a tumour marker for colorectal liver metastases. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[41] V. Torri,et al. Soluble stroma‐related biomarkers of pancreatic cancer , 2018, EMBO molecular medicine.
[42] R. Miceli,et al. Extracellular matrix proteins as diagnostic markers of breast carcinoma , 2018, Journal of cellular physiology.
[43] Cynthia A. Reinhart-King,et al. Targeting extracellular matrix stiffness to attenuate disease: From molecular mechanisms to clinical trials , 2018, Science Translational Medicine.
[44] C. Yeo,et al. Tumor-specific expression and alternative splicing of the COL6A3 gene in pancreatic cancer. , 2011, Surgery.
[45] Z. Werb,et al. Remodelling the extracellular matrix in development and disease , 2014, Nature Reviews Molecular Cell Biology.
[46] G. Vozzi,et al. ECM Remodeling in Breast Cancer with Different Grade: Contribution of 2D‐DIGE Proteomics , 2018, Proteomics.
[47] A. Ferruelo,et al. The role of matrix metalloproteinase MMP-9 and TIMP-2 tissue inhibitor of metalloproteinases as serum markers of bladder cancer. , 2013, Actas urologicas espanolas.
[48] K. Grabowski,et al. Serum levels of matrix metalloproteinase-2 and -9 and conventional tumor markers (CEA and CA 19-9) in patients with colorectal and gastric cancers , 2009, Clinical chemistry and laboratory medicine.
[49] G. Mælandsmo,et al. Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease , 2018, BMC Cancer.
[50] T. Pihlajaniemi,et al. Serum endostatin levels are elevated in colorectal cancer and correlate with invasion and systemic inflammatory markers , 2014, British Journal of Cancer.
[51] D. Fearon,et al. T cell exclusion, immune privilege, and the tumor microenvironment , 2015, Science.
[52] K. Ohba,et al. Expression of Matrix Metalloproteinase-7 on Cancer Cells and Tissue Endothelial Cells in Renal Cell Carcinoma: Prognostic Implications and Clinical Significance for Invasion and Metastasis , 2006, Clinical Cancer Research.
[53] Z. Werb,et al. Matrix Metalloproteinases: Regulators of the Tumor Microenvironment , 2010, Cell.
[54] S. Ergün,et al. Serum endostatin levels correlate with enhanced extracellular matrix degradation and poor patients' prognosis in bladder cancer , 2012, International journal of cancer.
[55] R. Kalluri,et al. Tumor stroma derived biomarkers in cancer , 2009, Cancer and Metastasis Reviews.
[56] Ju-Han Lee,et al. Plasma or serum TIMP-1 is a predictor of survival outcomes in colorectal cancer: a meta-analysis. , 2011, Journal of gastrointestinal and liver diseases : JGLD.
[57] R. Holder,et al. Serum matrix metalloproteinase 9 and colorectal neoplasia: a community-based evaluation of a potential diagnostic test , 2012, British Journal of Cancer.
[58] Jacob J. Kennedy,et al. Tumor microenvironment-derived proteins dominate the plasma proteome response during breast cancer induction and progression. , 2011, Cancer research.
[59] M. Karsdal,et al. Tumstatin, a Matrikine Derived from Collagen Type IVα3, is Elevated in Serum from Patients with Non–Small Cell Lung Cancer , 2018, Translational oncology.
[60] M. Karsdal,et al. Serum biomarkers reflecting specific tumor tissue remodeling processes are valuable diagnostic tools for lung cancer , 2014, Cancer medicine.
[61] P. Naredi,et al. Combining conventional and stroma-derived tumour markers in pancreatic ductal adenocarcinoma. , 2015, Cancer biomarkers : section A of Disease markers.
[62] M. Callari,et al. Complexity in the tumour microenvironment: Cancer associated fibroblast gene expression patterns identify both common and unique features of tumour-stroma crosstalk across cancer types. , 2015, Seminars in cancer biology.
[63] M. Karsdal,et al. Excessive collagen turnover products are released during colorectal cancer progression and elevated in serum from metastatic colorectal cancer patients , 2016, Scientific Reports.
[64] E. Wang,et al. A mass spectrometry-based plasma protein panel targeting the tumor microenvironment in patients with breast cancer. , 2013, Journal of proteomics.
[65] M. Papotti,et al. Progressive Increase of Matrix Metalloprotease-9 and Interleukin-8 Serum Levels during Carcinogenic Process in Human Colorectal Tract , 2012, PloS one.
[66] F. Liu,et al. Stroma derived COL6A3 is a potential prognosis marker of colorectal carcinoma revealed by quantitative proteomics , 2015, Oncotarget.
[67] S. Carr,et al. Extracellular matrix signatures of human primary metastatic colon cancers and their metastases to liver , 2014, BMC Cancer.
[68] Extracellular matrix specific protein fingerprints measured in serum can separate pancreatic cancer patients from healthy controls , 2013, BMC Cancer.
[69] J. Karlsson,et al. The extracellular matrix – the under‐recognized element in lung disease? , 2016, The Journal of pathology.
[70] Hans H Schild,et al. Breast cancer risk assessment: a non-invasive multiparametric approach to stratify patients by MMP-9 serum activity and RhoA expression patterns in circulating leucocytes , 2016, Amino Acids.
[71] J. Raufman,et al. The Role of Matrix Metalloproteinases in Colorectal Cancer , 2014, Cancers.
[72] Z. Werb,et al. The extracellular matrix: A dynamic niche in cancer progression , 2012, The Journal of cell biology.